Co-Diagnostics ( NASDAQ:CODX ) First Quarter 2024 Results Key Financial Results Net loss: US$9.31m (loss widened by 62...
Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2024 Earnings Call Transcript May 9, 2024 Co-Diagnostics, Inc. misses on earnings expectations. Reported EPS is $-0.31204 EPS, expectations were $-0.21. CODX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the […]
Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024.